# Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07017673/  
OnCo record `nct07017673` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, carboplatin and docetaxel in triple-negative breast cancer, run by Cedars-Sinai Medical Center, now recruiting.

## Summary

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT07017673 by Cedars-Sinai Medical Center, with a registry enrolment figure of 34 participants, started 2025-07-25 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab; Carboplatin; Docetaxel. Conditions listed: TNBC; TNBC - Triple-Negative Breast Cancer; Early Stage Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: "* High-risk early stage triple negative breast cancer (TNBC), defined by ER≤10%, PR≤10% and HER2 negative (by IHC or FISH), per ASCO/CAP guidelines". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07017673
- Phase: 2
- Setting: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer
- Sponsor: Cedars-Sinai Medical Center
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT07017673: https://clinicaltrials.gov/study/NCT07017673

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07017673.json